Whalesbook
The Competition Commission of India (CCI) has closed an investigation into allegations that 12 super-specialty hospitals in the Delhi-NCR region overcharged patients. The case, initiated by a 2015 complaint, examined whether these hospitals abused dominant market positions by setting excessive prices for services like room rentals, diagnostic tests, medical devices, and consumables.
The CCI concluded that no violation of Section 4 of the Competition Act, 2002, occurred. The Commission defined the relevant market as the broader super-speciality healthcare services sector in Delhi-NCR, rather than focusing on individual hospitals or specific services. This wider market view was key to dismissing the claims.
The CCI emphasized that patients seek integrated medical treatment, not isolated purchases of medicines or devices. It also noted that hospital rooms, due to their clinical function and integrated infrastructure, are different from standard accommodation. Similarly, hospital laboratories, operating 24/7 with patient care, are distinct from standalone diagnostic centers.
The Commission further clarified that charging up to the Maximum Retail Price (MRP) for medicines and consumables is not automatically illegal overpricing, as it must consider overall operational costs. A two-stage test for excessive pricing, requiring proof of prices being higher than costs and demonstrably unfair, was not met.
Although an initial probe into collusion, stemming from a complaint about disposable syringes against Becton Dickinson India and Max Super Specialty Hospital, Patparganj, found insufficient evidence, the CCI had expanded its investigation into potential hospital market abuses. Despite a Director General's report suggesting violations between 2015 and 2018, the full Commission disagreed, leading to the closure of all related applications.
This ruling has implications for India's healthcare sector, setting a precedent for how overcharging allegations will be handled. It suggests regulators will require strong evidence of both inflated costs and unfairness before finding competition law violations in healthcare services. The CCI's nuanced market analysis distinguishes hospital services from standalone products.